Overexpression of clusterin promotes angiogenesis via the vascular endothelial growth factor in primary ovarian cancer

Molecular Medicine Reports

Volumn 7, Issue 6, 2013, Pages 1726-1732

  Fu, Yanxia ^a   Yingrong, Lai ^a   Wang, Qiongjuan ^a   Liu, Xingyang ^a   He, Weipeng ^a   Zhang, Haihong ^b   Chunyang, Fan ^b,c   Yang, Guofen ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Clusterin; Immunohistochemistry; Ovarian cancer; Vascular endothelial growth factor

Indexed keywords

CLUSTERIN; VASCULOTROPIN;

ADULT; ARTICLE; CANCER STAGING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; OVARY CARCINOMA; OVARY TUMOR; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR CLASSIFICATION; TUMOR VASCULARIZATION;

CARCINOMA; CLUSTERIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; TISSUE ARRAY ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84877279673     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1436     Document Type: Article

References (22)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics. CA Cancer J Clin 62: 10-29, 2012.
2. Yang GF, Li XM and Xie D: Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gynecol Cancer 19: 1342-1346, 2009.
3. Trougakos IP and Gonos ES: Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 34: 1430-1448, 2002.
4. Rizzi F and Bettuzzi S: Clusterin (CLU) and prostate cancer. Adv Cancer Res 105: 1-19, 2009.
5. Albert JM, Gonzalez A, Massion PP, Chen H, Olson SJ, Shyr Y, Diaz R, Lambright ES, Sandler A, Carbone DP, Putnam JJ, Johnson DH and Lu B: Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol Biomarkers Prev 16: 1845-1851, 2007.
6. Pucci S, Bonanno E, Pichiorri F, Angeloni C and Spagnoli LG: Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 23: 2298-2304, 2004.
7. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M and Petito CK: Overexpression of clusterin in human breast carcinoma. Am J Pathol 157: 393-399, 2000.
8. Miyake H, Gleave M, Kamidono S and Hara I: Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 59: 150-154, 2002.
9. Lau SH, Sham JS, Xie D, Tzang CH, Tang D, Ma N, Hu L, Wang Y, Wen JM, Xiao G, Zhang WM, Lau GK, Yang M and Guan XY: Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 25: 1242-1250, 2006.
10. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983.
11. Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, Siegel N, Haymore BL, Leimgruber R and Feder J: Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 264: 20017-20024, 1989.
12. Geva E and Jaffe RB: Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertil Steril 74: 429-438, 2000.
13. Ramakrishnan S, Subramanian IV, Yokoyama Y and Geller M: Angiogenesis in normal and neoplastic ovaries. Angiogenesis 8: 169-182, 2005.
14. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G and Giavazzi R: Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 63: 5224-5229, 2003.
15. Matei D, Kelich S, Cao L, Menning N, Emerson RE, Rao J, Jeng MH and Sledge GW: PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther 6: 1951-1959, 2007.
16. Liao S, Liu J, Lin P, Shi T, Jain RK and Xu L: TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clin Cancer Res 17: 1415-1424, 2011.
17. Cao Z, Fang J, Xia C, Shi X and Jiang BH: trans-3,4,5′- Trihydroxystibene inhibits hypoxia-inducible factor 1α and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res 10: 5253-5263, 2004.
18. Masoumi MS, Amini A, Morris DL and Pourgholami MH: Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev 31: 143-162, 2012.
19. Liu LZ, Hu XW, Xia C, He J, Zhou Q, Shi X, Fang J and Jiang BH: Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic Biol Med 41: 1521-1533, 2006.
20. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
21. Hassan MK, Watari H, Han Y, Mitamura T, Hosaka M, Wang L, Tanaka S and Sakuragi N: Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel. J Exp Clin Cancer Res 30: 113, 2011.
22. Ferrara N, Hillan KJ and Novotny W: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333: 328-335, 2005.